AI Article Synopsis
- The study examined the effectiveness of NB-UVB monotherapy for treating generalized psoriasis (PLC) in 29 Vietnamese patients.
- Patients received treatment three times a week and showed an impressive 82.8% complete response rate after an average of 4.6 weeks.
- Mild side effects like skin irritation were noted, but there were no severe side effects or relapses within three months post-treatment, indicating NB-UVB is both effective and safe for managing PLC.
Article Abstract
Aim: This prospective clinical study presents the experiences with NB-UVB monotherapy in the treatment of PLC on Vietnamese patients.
Methods: We enrolled at National Hospital of Dermatology and Venereology (NHDV), Vietnam, 29 PLC patients with generalised disease involving at least 60% of the total body surface (based on Nine's Rule) and/or failed to respond to other modalities of treatment. Patients were treated with NB-UVB followed the guideline of the psoriatic treatment of AAD-2010, three times weekly.
Results: A complete response (CR) was seen in 24 out of 29 PLC patients (82.8%) with a mean cumulative dose of 9760.5 mJ/cm after a mean treatment period of 4.6 weeks (13.8 ± 7.4 exposures). Mild side effects were observed: 69% erythema minimum, 55.2% irritation related to dry skin. No severe side effects were seen during the study. No relapses occurred in 24 CR patients within a mean period of 3 months after the last treatment.
Conclusion: NB-UVB therapy is an effective and safe option for the treatment and management of PLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364744 | PMC |
| http://dx.doi.org/10.3889/oamjms.2019.055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!